Communicating Treatment Expectations and Care Logistics for Bispecific Therapy

The panel focuses on how clinicians communicate treatment expectations, risks, and logistical considerations when initiating bispecific antibody therapy for patients with relapsed or refractory lymphoma. The discussion begins with strategies for aligning therapy with patient goals. Dr. Perez emphasizes that understanding a patient’s priorities, whether maximizing response, minimizing risk, or reducing time spent in clinical settings, is a critical first step in shared decision-making. These preferences can influence both treatment selection and how clinicians frame discussions around efficacy and quality of life.

The panel also discusses how to explain expected clinical outcomes. Patients are typically informed that response rates with currently available bispecific antibodies are approximately 50% to 60%, with about half of responding patients achieving complete remission. For heavily pretreated patients, these results represent meaningful clinical benefit. Importantly, clinicians often emphasize that durability of response is particularly relevant for patients who achieve complete remission, as sustained remissions are possible with these immunotherapeutic agents. The panel notes that patients are often more concerned about the duration of benefit than the initial response rate alone. Discussions also address treatment duration, clarifying whether therapy is given for a fixed period or continued until disease progression or unacceptable toxicity.

Operational considerations for outpatient versus inpatient treatment are also explored. Patients suitable for outpatient management typically have stable disease, good performance status, reliable caregiver support, and proximity to the treating center. In contrast, inpatient monitoring may be preferred for patients with bulky disease, higher risk for CRS, limited support systems, or significant distance from the treatment center.

The panel highlights the importance of caregiver involvement and patient reliability in monitoring for early symptoms of CRS or neurologic toxicity. Patients must understand when and where to seek care, ideally returning to the treating institution to ensure that clinicians familiar with bispecific-related toxicities can rapidly intervene.